Indivior PLC

INDV

GB00BN4HT335

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:03 2024-06-14 EDT			5-day change	1st Jan Change
1,318 ^GBX	+3.37%		+3.05%	+11.22%

06-10	Indivior PLC Announces Dosing of First Subject with Indv-2000 in A Phase 2 Study Assessing the Safety and Efficacy of Indv-2000 in Individuals with Opioid Use Disorder	CI
05-23	Indivior Confirms FY24 Outlook	MT

Indivior plc Reaffirms Revenue Guidance for the Year 2024

May 23, 2024 at 07:15 am

Indivior PLC reaffirmed revenue guidance for the year 2024. For the period, the company expected net revenue of $1,240 million to $1,330 million (+18% at midpoint vs. Fiscal Year 2023).

Latest news about Indivior PLC

Indivior PLC Announces Dosing of First Subject with Indv-2000 in A Phase 2 Study Assessing the Safety and Efficacy of Indv-2000 in Individuals with Opioid Use Disorder	06-10	CI
Indivior Confirms FY24 Outlook	05-23	MT
Transcript : Indivior PLC - Shareholder/Analyst Call	05-23
Indivior reconfirms 2024 outlook amid NY-listing decision	05-23	AN
Indivior plc Reaffirms Revenue Guidance for the Year 2024	05-23	CI
The latest transactions by star managers	05-21
Indivior PLC Announces Board Committee Changes	05-10	CI
Deutsche Bank Kicks Off Indivior Coverage at Buy	05-03	MT
Jefferies cuts AJ Bell; Deutsche likes ConvaTec	05-03	AN
Transcript : Indivior PLC, Q1 2024 Earnings Call, Apr 25, 2024	04-25
London-listed Indivior Confirms Plan for Primary Listing in US	04-25	MT
Indivior Seeks Shareholder Nod for Listing in the United States	04-25	CI
UK-listed drugmaker Indivior seeks shareholder nod for US listing	04-25	RE
Indivior shares down despite profit boost on planned shift to New York	04-25	AN
Indivior Reports Higher Q1 Net Income, Net Revenue	04-25	MT
Tranche Update on Indivior PLC's Equity Buyback Plan announced on November 17, 2023.	04-25	CI
Indivior plc Reconfirms Earnings Guidance for 2024	04-25	CI
Indivior PLC Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Craig-Hallum Starts Indivior With Buy Rating, $37 Price Target	04-03	MT
C4X Discovery seeks AIM delisting but half-year revenue skyrockets	03-27	AN
Indivior PLC Appoints David E. Wheadon, M.D. as Independent Non-Executive Director, Effective from June 1, 2024	03-21	CI
Indivior CCO Richard Simkin sells GBP1 million in shares	03-18	AN
UBS cuts abrdn price target but ups Darktrace's	03-12	AN
Indivior Says Opvee Shows Drug Reverses Opioid-Induced Respiratory Depression Faster Than Naloxone	03-11	MT
Indivior PLC Announces Publication Demonstrating that OPVEE® Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone	03-11	CI

Indivior PLC is a pharmaceutical company. The Company develops medicines to treat addiction and serious mental illnesses. The Company focuses on building a portfolio of opioid dependence treatments. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as therapies to address the needs of people suffering from alcohol, stimulant, and cannabis use disorders. Its Sublocade, Subutex, and Suboxone are used for the treatment of opioid use disorder (OUD). Perseris is used for the treatment of Schizophrenia. The Company's pipeline products include AEF0117, INDV-2000, INDV-1000, RBP-6000, RBP-7000, Buprenorphine Sublingual and Naloxone Film, and Buprenorphine and Naloxone Sublingual Tablet. Its pipeline also includes the Orexin-1 Receptor Antagonist Program.

Sector

Pharmaceuticals

Calendar

2024-07-24 - Q2 2024 Earnings Release (Projected)

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Ratings for Indivior PLC

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.71 USD

Average target price

30.86 USD

Spread / Average Target

+84.63%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
INDIVIOR PLC	+11.22%	2.24B
KYOWA KIRIN CO. LTD.	+15.93%	9.25B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+42.06%	4.45B
SK BIOPHARMACEUTICALS CO., LTD.	-22.01%	4.43B
YUHAN CORPORATION	+8.28%	4.03B
BETTA PHARMACEUTICALS CO., LTD.	-26.61%	2.18B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+11.64%	2.02B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-42.69%	1.79B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B
SUPERNUS PHARMACEUTICALS, INC.	-10.19%	1.43B

Specialty & Advanced Pharmaceuticals

Indivior PLC

Equities

INDV

GB00BN4HT335

Pharmaceuticals

Indivior plc Reaffirms Revenue Guidance for the Year 2024

Latest news about Indivior PLC

Chart Indivior PLC

Company Profile

Income Statement Evolution

Ratings for Indivior PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals